A novel small molecule inhibitor of deubiquitylating enzyme USP14 and UCHL5 induces apoptosis in multiple myeloma and overcomes bortezomib resistance

Blood

Volumn 123, Issue 5, 2014, Pages 706-716

  Tian, Ze ^a   D'Arcy, Padraig ^b   Wang, Xin ^b   Ray, Arghya ^a   Tai, Yu Tzu ^a   Hu, Yiguo ^a   Carrasco, Ruben D ^a   Richardson, Paul ^a   Linder, Stig ^b   Chauhan, Dharminder ^a   Anderson, Kenneth C ^a  

^a HARVARD MEDICAL SCHOOL   (United States)

^b KAROLINSKA INSTITUTE   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

B AP15; BORTEZOMIB; CASPASE; DEUBIQUITYLATING ENZYME; DEXAMETHASONE; LENALIDOMIDE; PROTEASOME INHIBITOR; SMALL MOLECULE TRANSPORT AGENT; UBIQUITIN PROTEIN LIGASE; UCLH5 ENZYME; UNCLASSIFIED DRUG; USP14 ENZYME; VORINOSTAT; 3,5 BIS((4 NITROPHENYL)METHYLIDENE) 1 PROP 2 ENOYLPIPERIDIN 4 ONE; 3,5-BIS((4-NITROPHENYL)METHYLIDENE)-1-PROP-2-ENOYLPIPERIDIN-4-ONE; ANTINEOPLASTIC AGENT; BORONIC ACID DERIVATIVE; PIPERIDONE DERIVATIVE; PROTEINASE INHIBITOR; PYRAZINE DERIVATIVE; UBIQUITIN THIOLESTERASE; UCHL5 PROTEIN, HUMAN; USP14 PROTEIN, HUMAN;

ANIMAL EXPERIMENT; ANIMAL MODEL; APOPTOSIS; ARTICLE; BONE MARROW CELL; CANCER CELL LINE; CANCER INHIBITION; CANCER RESISTANCE; CANCER SURVIVAL; CELL PROLIFERATION; CELL VIABILITY; CLINICAL EVALUATION; CONTROLLED STUDY; DRUG POTENTIATION; DRUG TOLERABILITY; HUMAN; HUMAN CELL; IN VIVO STUDY; MOUSE; MULTIPLE MYELOMA; NONHUMAN; PLASMA CELL; PRIORITY JOURNAL; STROMA CELL; XENOGRAFT; ANIMAL; DRUG ANTAGONISM; DRUG EFFECT; DRUG RESISTANCE; ENDOPLASMIC RETICULUM STRESS; FEMALE; GENE EXPRESSION REGULATION; GENETICS; PATHOLOGY; TUMOR CELL LINE; UPREGULATION;

ANIMALS; ANTINEOPLASTIC AGENTS; APOPTOSIS; BORONIC ACIDS; CELL LINE, TUMOR; DRUG RESISTANCE, NEOPLASM; ENDOPLASMIC RETICULUM STRESS; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; MICE; MULTIPLE MYELOMA; PIPERIDONES; PROTEASE INHIBITORS; PYRAZINES; UBIQUITIN THIOLESTERASE; UP-REGULATION;

EID: 84897022669     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2013-05-500033     Document Type: Article

References (39)

1. Chauhan D, Catley L, Li G, et al. A novel orally active proteasome inhibitor induces apoptosis in multiple myeloma cells with mechanisms distinct from Bortezomib. Cancer Cell. 2005;8(5):407-419. (Pubitemid 41579835)
2. Lawasut P, Chauhan D, Laubach J, et al. New proteasome inhibitors in myeloma. Curr Hematol Malig Rep. 2012;7(4):258-266.
3. Reverdy C, Conrath S, Lopez R, et al. Discovery of specific inhibitors of human USP7/HAUSP deubiquitinating enzyme. Chem Biol. 2012;19(4):467-477.
4. Colland F. The therapeutic potential of deubiquitinating enzyme inhibitors. Biochem Soc Trans. 2010;38(Pt 1):137-143.
5. Song L, Rape M. Reverse the curse - the role of deubiquitination in cell cycle control. Curr Opin Cell Biol. 2008;20(2):156-163.
6. Yao T, Song L, Xu W, et al. Proteasome recruitment and activation of the Uch37 deubiquitinating enzyme by Adrm1. Nat Cell Biol. 2006;8(9):994-1002. (Pubitemid 44314731)
7. Reyes-Turcu FE, Ventii KH, Wilkinson KD. Regulation and cellular roles of ubiquitin-specific deubiquitinating enzymes. Annu Rev Biochem. 2009;78:363-397.
8. Adhikari A, Xu M, Chen ZJ. Ubiquitin-mediated activation of TAK1 and IKK. Oncogene. 2007;26(22):3214-3226. (Pubitemid 46763016)
9. Zhang D, Zaugg K, Mak TW, Elledge SJ. A role for the deubiquitinating enzyme USP28 in control of the DNA-damage response. Cell. 2006;126(3):529-542. (Pubitemid 44163600)
10. Lee BH, Lee MJ, Park S, et al. Enhancement of proteasome activity by a small-molecule inhibitor of USP14. Nature. 2010;467(7312):179-184.
11. Borodovsky A, Kessler BM, Casagrande R, Overkleeft HS, Wilkinson KD, Ploegh HL. A novel active site-directed probe specific for deubiquitylating enzymes reveals proteasome association of USP14. EMBO J. 2001;20(18):5187-5196. (Pubitemid 32910913)
12. Verma R, Aravind L, Oania R, McDonald WH, Yates JR III, Koonin EV, Deshaies RJ. Role of Rpn11 metalloprotease in deubiquitination and degradation by the 26S proteasome. Science. 2002;298(5593):611-615. (Pubitemid 35215317)
13. Wada T, Yamashita Y, Saga Y, et al. Screening for genetic abnormalities involved in ovarian carcinogenesis using retroviral expression libraries. Int J Oncol. 2009;35(5):973-976.
14. Shinji S, Naito Z, Ishiwata S, et al. Ubiquitin-specific protease 14 expression in colorectal cancer is associated with liver and lymph node metastases. Oncol Rep. 2006;15(3):539-543.
15. Mines MA, Goodwin JS, Limbird LE, Cui FF, Fan GH. Deubiquitination of CXCR4 by USP14 is critical for both CXCL12-induced CXCR4 degradation and chemotaxis but not ERK ativation. J Biol Chem. 2009;284(9):5742-5752.
16. Maiti TK, Permaul M, Boudreaux DA, Mahanic C, Mauney S, Das C. Crystal structure of the catalytic domain of UCHL5, a proteasome-associated human deubiquitinating enzyme, reveals an unproductive form of the enzyme. FEBS J. 2011;278(24):4917-4926.
17. Wicks SJ, Haros K, Maillard M, Song L, Cohen RE, Dijke PT, Chantry A. The deubiquitinating enzyme UCH37 interacts with Smads and regulates TGF-beta signalling. Oncogene. 2005;24(54):8080-8084. (Pubitemid 41746751)
18. Al-Shami A, Jhaver KG, Vogel P, et al. Regulators of the proteasome pathway, Uch37 and Rpn13, play distinct roles in mouse development. PLoS ONE. 2010;5(10):e13654.
19. Chen Y, Fu D, Xi J, et al. Expression and clinical significance of UCH37 in human esophageal squamous cell carcinoma. Dig Dis Sci. 2012;57(9):2310-2317.
20. D'Arcy P, Linder S. Proteasome deubiquitinases as novel targets for cancer therapy. Int J Biochem Cell Biol. 2012;44(11):1729-1738.
21. D'Arcy P, Brnjic S, Olofsson MH, et al. Inhibition of proteasome deubiquitinating activity as a new cancer therapy. Nat Med. 2011;17(12):1636- 1640.
22. Chauhan D, Tian Z, Zhou B, et al. In vitro and in vivo selective antitumor activity of a novel orally bioavailable proteasome inhibitor MLN9708 against multiple myeloma cells. Clin Cancer Res. 2011;17(16):5311-5321.
23. Chauhan D, Tian Z, Nicholson B, et al. A small molecule inhibitor of ubiquitin-specific protease-7 induces apoptosis in multiple myeloma cells and overcomes bortezomib resistance. Cancer Cell. 2012;22(3):345-358.
24. Tian Z, Zhao JJ, Tai YT, et al. Investigational agent MLN9708/2238 targets tumor-suppressor miR33b in MM cells. Blood. 2012;120(19):3958-3967.
25. Menéndez-Benito V, Verhoef LG, Masucci MG, Dantuma NP. Endoplasmic reticulum stress compromises the ubiquitin-proteasome system. Hum Mol Genet. 2005;14(19):2787-2799. (Pubitemid 41418785)
26. Tai YT, Chang BY, Kong SY, et al. Bruton tyrosine kinase inhibition is a novel therapeutic strategy targeting tumor in the bone marrow microenvironment in multiple myeloma. Blood. 2012;120(9):1877-1887.
27. Leung-Hagesteijn C, Erdmann N, Cheung G, et al. Xbp1s-negative tumor B cells and pre-plasmablasts mediate therapeutic proteasome inhibitor resistance in multiple myeloma. Cancer Cell. 2013;24(3):289-304.
28. Hu M, Li P, Song L, et al. Structure and mechanisms of the proteasome-associated deubiquitinating enzyme USP14. EMBO J. 2005;24(21):3747-3756. (Pubitemid 41581691)
29. Hussain S, Zhang Y, Galardy PJ. DUBs and cancer: the role of deubiquitinating enzymes as oncogenes, non-oncogenes and tumor suppressors. Cell Cycle. 2009;8(11):1688-1697.
30. Nicholson B, Marblestone JG, Butt TR, Mattern MR. Deubiquitinating enzymes as novel anticancer targets. Future Oncol. 2007;3(2):191-199. (Pubitemid 46592727)
31. Fraile JM, Quesada V, Rodríguez D, Freije JM, López- Otín C. Deubiquitinases in cancer: new functions and therapeutic options. Oncogene. 2012;31(19):2373-2388.
32. Trudel S, Li ZH, Wei E, et al. CHIR-258, a novel, multitargeted tyrosine kinase inhibitor for the potential treatment of t(4;14) multiple myeloma. Blood. 2005;105(7):2941-2948. (Pubitemid 40446289)
33. Kapuria V, Peterson LF, Fang D, Bornmann WG, Talpaz M, Donato NJ. Deubiquitinase inhibition by small-molecule WP1130 triggers aggresome formation and tumor cell apoptosis. Cancer Res. 2010;70(22):9265-9276.
34. Izumi T, Maller JL. Elimination of cdc2 phosphorylation sites in the cdc25 phosphatase blocks initiation of M-phase. Mol Biol Cell. 1993;4(12):1337-1350. (Pubitemid 24045763)
35. Chen F, Zhang Z, Bower J, et al. Arsenite-induced Cdc25C degradation is through the KEN-box and ubiquitin-proteasome pathway. Proc Natl Acad Sci USA. 2002;99(4):1990-1995. (Pubitemid 34169002)
36. Xiao D, Johnson CS, Trump DL, Singh SV. Proteasome-mediated degradation of cell division cycle 25C and cyclin-dependent kinase 1 in phenethyl isothiocyanate-induced G2-M-phase cell cycle arrest in PC-3 human prostate cancer cells. Mol Cancer Ther. 2004;3(5):567-575. (Pubitemid 39193735)
37. Abbas T, Dutta A. p21 in cancer: intricate networks and multiple activities. Nat Rev Cancer. 2009;9(6):400-414.
38. Luo D, He Y, Zhang H, et al. AIP1 is critical in transducing IRE1-mediated endoplasmic reticulum stress response. J Biol Chem. 2008;283(18):11905-11912.
39. Hotamisligil GS. Endoplasmic reticulum stress and the inflammatory basis of metabolic disease. Cell. 2010;140(6):900-917.